Development of dual V1a/V2 antagonists containing triazolobenzazepine scaffold

  • Eur J Med Chem. 2024 Nov 28:283:117069. doi: 10.1016/j.ejmech.2024.117069.
Gábor Varró  1 ,  Éva Bozó  2 ,  Krisztina Vukics  2 ,  Ferenc Baska  2 ,  Gábor Szántó  2 ,  Balázs Krámos  2 ,  Katalin Domány-Kovács  2 ,  Krisztina Szondiné Kordás  2 ,  Mónika Vastag  2 ,  Ildikó Magdó  2 ,  Imre Bata  2
Affiliations
  • 1. Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary. Electronic address: [email protected].
  • 2. Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary.
PMID: 39631099 DOI: 10.1016/j.ejmech.2024.117069
Abstract

The development of a dual V1a/V2 antagonist compound is a complex and challenging task. Conivaptan is up to now the only known V1a/V2 antagonist which was approved for the treatment of euvolemic hyponatremia. Previously, we reported RGH-122, a novel selective V1a antagonist compound. Herein, we describe several promising dual antagonist compounds, which are derived from RGH-122 by using modifications in its tail region. These modifications can result in excellent binding affinity on both V1a and V2 receptors.

Keywords
In silico docking; Triazolobenzazepine; V1a/V2 dual antagonist.
Products